R&D
Introducing our business areas and technologies.
Technology_New Drug
| Pipeline Name | Indication | HIT Lead Preclinical Phase I Phase II Phase III NDA |
|---|---|---|
| MB-D-007 | Insulin sensitizer | |
| MB-N-008 | NASH | |
| MB-C-011 | Cancer (kinase inhibitor) |
|
| MB-CV-021 | cancer vaccine (peptide molecule) |
|
| MB-AC-32 | Cancer (Autophagy) |
MB-D-007
- Insulin sensitizer
MB-N-008
- NASH
MB-C-011
- Cancer
MB-CV-021
- Cancer
MB-AC-32
- Cancer
C.E.O : Bo Sung Ku Tel : +82-31-888-9500 Fax : +82-31-888-9981
Copyright © 2021 MBD www.mbdbiotech.com All Rights Reserved.